Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

NCT07276373 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Nenocorilant 200 mg
DRUG: Nenocorilant 300 mg
DRUG: Nenocorilant 400 mg
DRUG: Nivolumab

Sponsor

Corcept Therapeutics